Oxidized low-density lipoprotein (oxLDL) affects load-free cell shortening of cardiomyocytes in a proprotein convertase subtilisin/kexin 9 (PCSK9)-dependent way

Abstract

Recent studies have documented that oxidized low-density lipoprotein cholesterol (oxLDL) levels directly impact myocardial structure and function. However, the molecular mechanisms by which oxLDL affects cardiac myocytes are not well established. We addressed the question whether oxLDL modifies load-free cell shortening, a standardized readout of cardiac cellular function, and investigated whether proprotein convertase subtilisin/kexin-9 (PCSK9) is involved on oxLDL-dependent processes. Adult rat ventricular cardiomyocytes were isolated and incubated for 24 h with oxLDL. PCSK9 was silenced by administration of siRNA. Load-free cell shortening was analyzed via a line camera at a beating frequency of 2 Hz. RT-PCR and immunoblots were used to identify molecular pathways. We observed a concentration-dependent reduction of load-free cell shortening that was independent of cell damage (apoptosis, necrosis). The effect of oxLDL was attenuated by silencing of oxLDL receptors (LOX-1), blockade of p38 MAP kinase activation, and silencing of PCSK9. oxLDL increased the expression of PCSK9 and caused oxidative modification of tropomyosin. In conclusion, we found that oxLDL significantly impaired contractile function via induction of PCSK9. This is the first report about the expression of PCSK9 in adult terminal differentiated ventricular cardiomyocytes. The data are important in the light of recent development of PCSK9 inhibitory strategies.Electronic supplementary materialThe online version of this article (doi:10.1007/s00395-017-0650-1) contains supplementary material, which is available to authorized users.

RETRACTED ARTICLE: Sirtuin 3 inhibition induces mitochondrial stress in tongue cancer by targeting mitochondrial fission and the JNK-Fis1 biological axis

“…Besides, Sirt3 knockout also leads to c-Jun N-terminal kinases (JNK) pathway activation and ROS overproduction (Jing et al 2011). These data confirm the tumor-suppressive property of Sirt3 inhibition on cancer survival, metabolism, and invasion (Schluter et al 2017). Interestingly, no study has explored the detailed role of Sirt3 in tongue cancer.…”

Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products

“…The C-type lectin domain is critical for oxLDL binding. In terms of expression, LOX-1 is ubiquitously expressed in vascular cells, such as endothelial cells (Sawamura et al, 1997), macrophages (Draude et al, 1999), VSMCs (Zhang et al, 2017), cardiomyocytes (Schlüter et al, 2017), and fibroblasts (Liu et al, 2016a). The ubiquitous expression pattern of LOX-1 in cardiovascular cells implicates its important role in regulating cardiovascular pathophysiology.…”

Targeting LOX‐1 in atherosclerosis and vasculopathy: current knowledge and future perspectives

“…Lectin‐like ox‐LDL receptor‐1 (LOX‐1, also known as oxidized LDL receptor 1 (OLR1)), represents one of the major SRs that binds ox‐LDL in ECs . Although initially identified as a major receptor for ox‐LDL in ECs, LOX‐1 is also expressed in macrophages, VSMCs, smooth muscle progenitor cells, cardiomyocytes, fibroblasts, adipocytes, airway epithelial cells, interferon γ‐conditioned dendritic cells, other myeloid cells, and platelets . More importantly, LOX‐1 is highly expressed in advanced atherosclerotic lesions, for example, in the model of the Watanabe heritable hyperlipidemic (WHHL) rabbits .…”